1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Merck Readies To Defend Januvia, Keytruda Franchises

 
• By Lisa LaMotta

Merck & Co. Inc. is relying heavily on its diabetes and immuno-oncology franchises, but the big pharma is facing new competitive threats in those areas that will require the company to defend its leadership positions.

The New Jersey-based pharma giant had a strong third quarter that beat analysts' bottom-line expectations, bolstered by sales of its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.

More from Therapy Areas

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.